In this in-depth conversation, Elen Baloyan speaks with Dr. Karen Knudsen, Chief Executive Officer of the Parker Institute for Cancer Immunotherapy, about a significant new collaboration with ASCO and Conquer Cancer to support the next generation of leaders in cancer immunotherapy. As cancer therapeutics enter a new era driven increasingly by immunotherapy, the need for well-trained clinical investigators has never been greater.
Dr. Knudsen shares insights into the Parker Institute’s strategy to fund bold, game-changing science, curate discoveries across the development pipeline, and ensure innovative therapies reach clinical testing.
Key topics discussed:
- The vision behind the Parker Institute’s partnership with ASCO and Conquer Cancer
- Why supporting early-career clinical investigators is critical at this moment
- The shortage of clinical researchers and the need to build sustainable career pathways
- How immunotherapy is driving the next phase of declining cancer mortality
- The importance of bench-to-bedside research in award selection
- Why global collaboration and “learning from every patient” will define the next decade of oncology
This episode offers valuable insights for researchers, clinicians, trainees, and anyone interested in the evolving future of cancer immunotherapy and translational research.